The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases.
The study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria
• Patients suffering from neurodegenerative diseases
Exclusion Criteria
• Patients not suffering from neurodegenerative diseases
Primary outcome measure(s)
Identify variants in our genetic makeup, proteins, and/or altered metabolic pathways in patients with neurodegenerative diseases — 10 years Thanks to the integration of genomic, gene expression, protein and metabolic data and clinical data, the Firm aims to identify new markers for diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases. There will be three outcomes from the study.
* Identification of variants in our coding DNA (i.e. that serves to produce proteins needed by our cells) that are known to cause or predispose to Alzheimer's disease;
* Analyze the non-coding regions of our DNA (i.e. regions that serve to regulate, modify, inhibit the production of proteins in our body) in search of variants that can cause, modify the prognosis and/or response to drugs in Alzheimer's disease;
* Investigate the role of genetic-molecular alterations on the clinical phenotype for the most frequent variants
Trial sites (1)
Facility
City
Region
Status
Ospedale Policlinico San Martino
Genoa
Genoa
Recruiting
More Ospedale Policlinico San Martino trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
